BioWorld

Sep. 9, 2005

Replidyne Raises $62.5M; Health Care Remains Top Dog For VCs

As its first product nears the market for respiratory infections, Replidyne Inc. brought in $62.5 million in a Series D round. (BioWorld Today) Read More

Alliance Shifts Astral Subsidiary To MultiCell, Retains One-Third

Amicus Series C Garners $55M For Enzyme Efforts

Caliper Adding Size Through $22M NovaScreen Purchase

NeuroHealing Tackling Brain Injury With Dopamine Agonist

Life Science Firms Giving To Help Katrina's Victims

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Jan 30, 2025.

Today's news in brief

Briefs

BioWorld MedTech briefs for Jan. 30, 2026.

Brain-derived tau in blood predicts stroke severity and outcome

BioWorld Science

Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...

Centessa’s CNT-9982 shows promise for MDD

BioWorld Science

Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...

First-in-class ADC targeting DEM-TXX shows high preclinical efficacy

BioWorld Science

Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...